PTGS2 and breast carcinoma: Since we observed higher levels of PPARα in breast cancer cells versus HMEC cells, we next evaluated the effect of clofibrate treatment on COX-2 inflammatory pathway enzymes and their receptors in breast cancer cells (Figure 5A).